Latest articles for Psoriasis
JAK inhibitor safety warnings drawn from rheumatologic data may be misleading in dermatology
The recently approved deucravacitinib is the only JAK inhibitor that has so far been exempt from these warnings.
Pediatric Dermatology Consult
A 9-year-old male presents with multiple thick scaly plaques on scalp, ears, and trunk
A nine-year-old boy presents with thick, scaly plaques on scalp, ears, and trunk.
From the Journals
Biologics show signs of delaying arthritis in psoriasis patients
Treatment with the interleukin-12/23 inhibitor ustekinumab or interleukin-23 inhibitors (guselkumab, risankizumab, tildrakizumab) was linked to a...
Dermatologic Implications of Sleep Deprivation in the US Military
In this article, we explore possible mechanisms by which sleep deprivation may affect the skin. We also review the potential impacts of sleep...
From the Journals
Isolated nail psoriasis may bring arthritis into play
The review of 20 years of cases show delayed diagnosis, delineate clinical features, and suggest a relationship with PsA.
Treating nail psoriasis: Intralesional injections and biologics
When Dr. Armstrong performs intramatricial injections, she uses triamcinolone acetonide at 10 mg/mL.
What’s holding back physicians from prescribing biosimilars? Four specialties weigh in
Physicians surveyed from four different specialties reported that they were generally comfortable prescribing biosimilars, but greater discounts...
New influx of Humira biosimilars may not drive immediate change
As many as 8-10 adalimumab biosimilars are anticipated to come on the market this year, giving mainstay drug Humira some vigorous competition.
What does the future of psoriasis treatment look like?
“We have terrific drugs for psoriasis, but how can we do better?” Dr. Andrew Blauvelt asked.
PsA prediction tool approaches clinical utility
A tool to identify patients with psoriasis at high risk of psoriatic arthritis appears near to clinical application.